Previous 10 | Next 10 |
TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced do...
SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual inve...
SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Z...
The following slide deck was published by Zai Lab Limited in conjunction with their 2021 Q1 earnings call. For further details see: Zai Lab Limited 2021 Q1 - Results - Earnings Call Presentation
Zai Lab Limited (ZLAB) Q1 2021 Earnings Conference Call May 10, 2021 08:00 ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson & Chief Executive Officer Tao Fu - Chief Operating Officer Jonathan Wang - Head of Business Development Alan Sandler - ...
Zai Lab (ZLAB): Q1 GAAP EPS of -$2.64 misses by $1.78.Revenue of $20.1M (+145.1% Y/Y) beats by $2.44M.Cash and cash equivalents, short-term investments and restricted cash of $1,014.2MPress Release For further details see: Zai Lab EPS misses by $1.78, beats on revenue
SHANGHAI and SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results for the first quarter of 2021, along with recent product highlights and corporate updates. ...
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage ...
SHANGHAI and SAN FRANCISCO, April 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2021, and provide a corporate upda...
Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. Shanghai Junshi Bio completed its $50 million investment into its US partner, Coherus BioSciences. Tianjin CanSino Biologics will start a clinical trial of an inhaled COVID-19 va...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...